论文部分内容阅读
The pharmacodynamics of Annexin32, a new Ca2+-dependent phospholipid-binding protein, was studied by measuring coagulation time in rabbits and venous thrombosis in rabbits and rats. Rabbits and rats were given Annexin32 by intravenous administration. Then Kaolin partial thromboplastin time (KPTT), thrombosis in vitro and in vivo were assayed. The results showed that KPTT of rabbits was prolonged (p < 0.01), and the length and weight of thrombus in vitro were reduced (p < 0.01) after administration of Annexin32 at 1 mg/kg. It also inhibited thrombosis in vivo and reduced the weight of venous thrombus significantly in rats (p < 0.01). All these results suggested that Annexin32 possesses the characteristic of antithrombotic effect and fewer side effects on coagulation time.
The pharmacodynamics of Annexin 32, a new Ca2 + -dependent phospholipid-binding protein, was studied by measuring coagulation time in rabbits and venous thrombosis in rabbits and rats. Rabbits and rats were given Annexin 32 by intravenous administration. Then Kaolin partial thromboplastin time (KPTT), Thrombosis in vitro and in vivo were assayed. The results showed that KPTT of rabbits was prolonged (p <0.01), and the length and weight of thrombus in vitro were reduced (p <0.01) after administration of Annexin 32 at 1 mg / kg. It also inhibits thrombosis in vivo and reduced the weight of venous thrombus significantly in rats (p <0.01). All these results suggest that Annexin 32 possesses the characteristic of antithrombotic effect and fewer side effects on coagulation time.